TOPLINE:<\/h2>\n
In patients with HER2-positive breast cancer brain metastases, treatment with trastuzumab deruxtecan was associated with a 10% incidence rate of interstitial lung disease (ILD)\/pneumonitis, with 2% of patients experiencing events of grade 3 or higher and 11% discontinuing treatment. Although no fatal lung complications occurred, the findings highlight the need for careful monitoring in this high-risk population.<\/p>\n
METHODOLOGY:<\/h2>\n\n- HER2-positive breast cancer frequently metastasizes to the brain, and prior HER2-directed therapies have shown limited intracranial activity. Trastuzumab deruxtecan, a next-generation antibody-drug conjugate, has demonstrated marked intracranial benefits but carries a risk for ILD\/pneumonitis. Previous studies have analyzed its safety profile in the general HER2-positive population but have not specifically analyzed outcomes in patients with breast cancer brain metastases.<\/li>\n
- To address this gap, researchers conducted a systematic review and meta-analysis of nine studies involving 684 patients with HER2-positive breast cancer brain metastases. Most studies included patients with a median age of 51-55 years; 63% had hormone receptor-positive tumors, and the mean follow-up duration was 16 months.<\/li>\n
- Study outcomes were occurrences of various treatment-emergent adverse events (TEAEs) associated with trastuzumab deruxtecan, with a specific focus on the incidence and severity of ILD\/pneumonitis.<\/li>\n<\/ul>\n
TAKEAWAY:<\/h2>\n\n- The pooled incidence rates of ILD\/pneumonia of all grades and grade 3 or higher were 10% (95% CI, 5%-16%) and 2% (95% CI, 1%-4%), respectively; ILD\/pneumonitis prompted treatment discontinuation in 11% (95% CI, 0%-24%) of patients.<\/li>\n
- Overall, TEAEs occurred in 97% of patients, with events of grade 3 or higher occurring in 48%. Fatigue and nausea were the most common all\u2010grade TEAEs, occurring in 67% and 60% of patients with breast cancer brain metastases, respectively.<\/li>\n
- The rate of any fatal TEAEs was 1% (95% CI, 0%-4%). No fatal cases of ILD\/pneumonitis were reported in the analyzed cohort, which is \u201cin\u2026contrast to the 2.3% fatal ILD\/pneumonitis rate documented in the [breast cancer brain metastasis] cohort of DESTINY-Breast12,\u201d the authors wrote.<\/li>\n
- Subgroup analyses suggested higher rates of all-grade ILD\/pneumonia and higher rates of events of grade 3 or higher in 2024 studies; however, none of these subgroup differences reached statistical significance.<\/li>\n<\/ul>\n
IN PRACTICE:<\/h2>\n
\u201cThis meta\u2010analysis provides essential safety data specific to this population, confirming that ILD\/pneumonitis remains a prevalent and clinically significant TEAE, leading to treatment discontinuation in a fraction of patients,\u201d the authors wrote. Although no fatal ILD events were observed, \u201cthe potential association between [brain metastasis] and heightened susceptibility to ILD\/pneumonitis highlights the essential need for vigilant monitoring and proactive management to improve survival outcomes in these patients.\u201d<\/p>\n
SOURCE:<\/h2>\n
The study, led by Yiwen Ma, PhD, Cancer Hospital of Dalian University of Technology, Shenyang, China, was published online in Cancer<\/em>.<\/p>\nLIMITATIONS:<\/h2>\n
The included studies were predominantly retrospective or subgroup analyses of larger trials, which might have introduced potential selection bias in ILD\/pneumonitis monitoring and management protocols. The analysis showed moderate-to-high heterogeneity in pooled estimates, whereas some studies had relatively short median follow-up times that might have underestimated late-onset ILD\/pneumonitis events. Additionally, potential confounding factors such as brain metastases activity, proportion of lung metastases, and prior anti-HER2 treatment strategies could not be assessed through subgroup analysis due to inconsistent reporting across studies.<\/p>\n
DISCLOSURES:<\/h2>\n
The study received support from multiple grants, including Liaoning Provincial Key R&D Projects, Shenyang Public Health R&D Special Project, Shenyang Breast Cancer Clinical Medical Research Center (2020-48-3-1), Liaoning Province Joint Fund Project, and Liaoning Cancer Hospital Oncology+ Project. The authors reported having no relevant conflicts of interest.<\/p>\n
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
TOPLINE: In patients with HER2-positive breast cancer brain metastases, treatment with trastuzumab deruxtecan was associated with a 10% incidence rate of interstitial lung disease (ILD)\/pneumonitis, with 2% of patients experiencing events of grade 3 or higher and 11% discontinuing treatment. Although no fatal lung complications occurred, the findings highlight the need for careful monitoring in […]<\/p>\n","protected":false},"author":1,"featured_media":19357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-19356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/02\/dt_230628_interstitial_lung_disease_800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=19356"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/19357"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=19356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=19356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=19356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
TAKEAWAY:<\/h2>\n\n- The pooled incidence rates of ILD\/pneumonia of all grades and grade 3 or higher were 10% (95% CI, 5%-16%) and 2% (95% CI, 1%-4%), respectively; ILD\/pneumonitis prompted treatment discontinuation in 11% (95% CI, 0%-24%) of patients.<\/li>\n
- Overall, TEAEs occurred in 97% of patients, with events of grade 3 or higher occurring in 48%. Fatigue and nausea were the most common all\u2010grade TEAEs, occurring in 67% and 60% of patients with breast cancer brain metastases, respectively.<\/li>\n
- The rate of any fatal TEAEs was 1% (95% CI, 0%-4%). No fatal cases of ILD\/pneumonitis were reported in the analyzed cohort, which is \u201cin\u2026contrast to the 2.3% fatal ILD\/pneumonitis rate documented in the [breast cancer brain metastasis] cohort of DESTINY-Breast12,\u201d the authors wrote.<\/li>\n
- Subgroup analyses suggested higher rates of all-grade ILD\/pneumonia and higher rates of events of grade 3 or higher in 2024 studies; however, none of these subgroup differences reached statistical significance.<\/li>\n<\/ul>\n
IN PRACTICE:<\/h2>\n
\u201cThis meta\u2010analysis provides essential safety data specific to this population, confirming that ILD\/pneumonitis remains a prevalent and clinically significant TEAE, leading to treatment discontinuation in a fraction of patients,\u201d the authors wrote. Although no fatal ILD events were observed, \u201cthe potential association between [brain metastasis] and heightened susceptibility to ILD\/pneumonitis highlights the essential need for vigilant monitoring and proactive management to improve survival outcomes in these patients.\u201d<\/p>\n
SOURCE:<\/h2>\n
The study, led by Yiwen Ma, PhD, Cancer Hospital of Dalian University of Technology, Shenyang, China, was published online in Cancer<\/em>.<\/p>\nLIMITATIONS:<\/h2>\n
The included studies were predominantly retrospective or subgroup analyses of larger trials, which might have introduced potential selection bias in ILD\/pneumonitis monitoring and management protocols. The analysis showed moderate-to-high heterogeneity in pooled estimates, whereas some studies had relatively short median follow-up times that might have underestimated late-onset ILD\/pneumonitis events. Additionally, potential confounding factors such as brain metastases activity, proportion of lung metastases, and prior anti-HER2 treatment strategies could not be assessed through subgroup analysis due to inconsistent reporting across studies.<\/p>\n
DISCLOSURES:<\/h2>\n
The study received support from multiple grants, including Liaoning Provincial Key R&D Projects, Shenyang Public Health R&D Special Project, Shenyang Breast Cancer Clinical Medical Research Center (2020-48-3-1), Liaoning Province Joint Fund Project, and Liaoning Cancer Hospital Oncology+ Project. The authors reported having no relevant conflicts of interest.<\/p>\n
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
TOPLINE: In patients with HER2-positive breast cancer brain metastases, treatment with trastuzumab deruxtecan was associated with a 10% incidence rate of interstitial lung disease (ILD)\/pneumonitis, with 2% of patients experiencing events of grade 3 or higher and 11% discontinuing treatment. Although no fatal lung complications occurred, the findings highlight the need for careful monitoring in […]<\/p>\n","protected":false},"author":1,"featured_media":19357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-19356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/02\/dt_230628_interstitial_lung_disease_800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=19356"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/19357"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=19356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=19356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=19356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
IN PRACTICE:<\/h2>\n
\u201cThis meta\u2010analysis provides essential safety data specific to this population, confirming that ILD\/pneumonitis remains a prevalent and clinically significant TEAE, leading to treatment discontinuation in a fraction of patients,\u201d the authors wrote. Although no fatal ILD events were observed, \u201cthe potential association between [brain metastasis] and heightened susceptibility to ILD\/pneumonitis highlights the essential need for vigilant monitoring and proactive management to improve survival outcomes in these patients.\u201d<\/p>\n
SOURCE:<\/h2>\n
The study, led by Yiwen Ma, PhD, Cancer Hospital of Dalian University of Technology, Shenyang, China, was published online in Cancer<\/em>.<\/p>\n The included studies were predominantly retrospective or subgroup analyses of larger trials, which might have introduced potential selection bias in ILD\/pneumonitis monitoring and management protocols. The analysis showed moderate-to-high heterogeneity in pooled estimates, whereas some studies had relatively short median follow-up times that might have underestimated late-onset ILD\/pneumonitis events. Additionally, potential confounding factors such as brain metastases activity, proportion of lung metastases, and prior anti-HER2 treatment strategies could not be assessed through subgroup analysis due to inconsistent reporting across studies.<\/p>\n The study received support from multiple grants, including Liaoning Provincial Key R&D Projects, Shenyang Public Health R&D Special Project, Shenyang Breast Cancer Clinical Medical Research Center (2020-48-3-1), Liaoning Province Joint Fund Project, and Liaoning Cancer Hospital Oncology+ Project. The authors reported having no relevant conflicts of interest.<\/p>\n This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n TOPLINE: In patients with HER2-positive breast cancer brain metastases, treatment with trastuzumab deruxtecan was associated with a 10% incidence rate of interstitial lung disease (ILD)\/pneumonitis, with 2% of patients experiencing events of grade 3 or higher and 11% discontinuing treatment. Although no fatal lung complications occurred, the findings highlight the need for careful monitoring in […]<\/p>\n","protected":false},"author":1,"featured_media":19357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-19356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/02\/dt_230628_interstitial_lung_disease_800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=19356"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/19356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/19357"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=19356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=19356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=19356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}LIMITATIONS:<\/h2>\n
DISCLOSURES:<\/h2>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"